Lymphocyte subsets in peripheral blood of patients with psoriasis before and after treatment with leishmania antigens.
Peripheral blood mononuclear cells (PBMC) collected from subjects prior to treatment and post-treatment with a vaccine composed of leishmania antigens were analyzed by flow cytometry. Upon analysis, it was noticed that lymphocyte subsets (LS) varied with psoriasis area and severity index (PASI) range (1-10, 11-20 and 21-72). Pre-treatment absolute values of gated LS were as follows. CD4+CD8-, CD3+CD8-, CD8+CD3+, CD8+CD4- and CD8+HLA- decreased in PBMC as PASI increased, suggesting migration from the blood to the skin. Contrary to the previous finding, the following LS, CD8+HLA+ and HLA+CD8-, and membrane surface immunoglobulin IgA+, IgD+ and IgM+ increased in PBMC as PASI increased, suggesting activation and proliferation by unknown antigens. After treatment with seven doses of AS100, the following LS, CD3+CD8-, CD8+CD3-, HLA+CD8-, CD8+HLA+ and CD4+CD8-, increased, while CD8+CD3+, CD8+HLA-, CD19 and CD8+CD4+ decreased in PBMC.
O'Daly
Jose Antonio
JA
Astralis LTD., 75 Passaic Ave., Fairfield, NJ 07004, USA. joseodaly@aol.com
Rodriguez
Beatriz
B
Ovalles
Tania
T
Pelaez
Civel
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007891:Leishmania / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016052:Protozoan Vaccines / Q000627:therapeutic use*; D011565:Psoriasis / Q000276:immunology / Q000628:therapy*
D016052:Protozoan Vaccines